# Study of Olverembatinib (HQP1351) in Patients With CP-CML

> **NCT06423911** · PHASE3 · RECRUITING · sponsor: **Ascentage Pharma Group Inc.** · enrollment: 285 (estimated)

## Conditions studied

- Chronic Myeloid Leukemia
- CML
- CML, Chronic Phase

## Interventions

- **DRUG:** olverembatinib
- **DRUG:** Bosutinib

## Key facts

- **NCT ID:** NCT06423911
- **Lead sponsor:** Ascentage Pharma Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-05
- **Primary completion:** 2025-12
- **Final completion:** 2026-02
- **Target enrollment:** 285 (ESTIMATED)
- **Last updated:** 2025-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06423911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06423911, "Study of Olverembatinib (HQP1351) in Patients With CP-CML". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06423911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*